NEVILLE REGISTRARS LIMITED

ABOUT NEVILLE REGISTRARS LIMITED

An international specialty pharmaceutical company focused on developing and commercialising products in oncology and other therapeutic areas.

Midatech is commercialising oncology treatment and supportive care products through its US commercial organisation, Midatech Pharma US (“Midatech US”) (formerly DARA BioSciences, Inc.). In Europe, Midatech is developing a pipeline of product candidates in clinical and pre-clinical development for diseases for which there are currently few or no treatment options available. These diseases include rare cancers including brain (glioblastoma, DIPG), and liver cancer.

Midatech’s strategy is to expand its US commercial arm as well as develop its products in-house in orphan oncology and with partners in other indications, and to accelerate growth of its business through strategic acquisition of complementary products and technologies.

All of Midatech’s product candidates derive from its two multi-applicable platform technologies that can be used alone or in combination to enable the targeted delivery (‘right place’) and controlled release (‘right time’) of existing drugs.

Midatech is collaborating with a number of universities, and specialty and major pharmaceutical companies to develop its platform technologies into a broad number of products in order to achieve a range of potential revenue opportunities within priority therapeutic areas.

International specialty pharmaceutical company focused on targeted therapies for rare diseases with unmet medical need.

We are committed to improving patients’ lives and to delivering and creating value for all our stakeholders.

Neville Registrars are only able to deal with enquiries from existing investors and are not able to respond to requests to purchase shares in Midatech Pharma plc.